AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01043757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives for increasing physical exercise
Description: Throughout the 12-week intervention, participants will receive step goals. The step goals will increase by 250 steps per week, The intervention will last a total of 12 weeks. After each seven-day week, step goals will increase by an additional 250 steps - thus over the 12 weeks, participants will be asked to increase their daily step count by 3,000. Participants will receive financial incentives to attain these step goals; the incentive schemes differ according to intervention arm.
Study NCT03429946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Participants will receive spironolactone 12 hours and 3 hours before the initiation of the hyperinsulinemic clamp treatment.
Study NCT03429946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo 12 hours and 3 hours before the initiation of the hyperinsulinemic clamp treatment.
Study NCT03429946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo 12 hours and 3 hours before the initiation of the hyperinsulinemic clamp treatment.
Study NCT03429946 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoglycemic Hyperinsulinemic Clamp
Description: Participants undergo two 120-minute hypoglycemic (50 mg/dL) hyperinsulinemic clamps - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
Study NCT03429946 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Euglycemic Hyperinsulinemic Clamp
Description: Participants undergo two 120-minute euglycemic (90 mg/dL) hyperinsulinemic clamps - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit.Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
Study NCT00276575 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00276575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Study NCT00276575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study NCT02760082 — intervention group
Intervention type: OTHER
Intervention: Qualitative evaluation
Study NCT03373565 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial
Description: Coronary angiography using radial approach
Study NCT03373565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palmar
Description: Coronary angiography using radial approach
Study NCT02424838 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNA of pancreatic masses
Description: EUS-FNA of pancreatic masses will be performed using a 22 or a 25 gauge needle with or without applying suction.
Study NCT02424838 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22 gauge needle
Study NCT02424838 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 25 gauge needle
Study NCT02910245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine (Purinethol)
Study NCT02910245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02910245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Study NCT02910245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mesalamine
Study NCT02910245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Study NCT02910245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Study NCT00634569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flebogamma 5% DIF
Description: Intravenous Immune Globulin (Human)
Study NCT02101970 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids
Description: Amber 4020 Ethyl Ester (EE) 1000 mg omega-3 capsule contains 420 mg of EPA and 210 mg of DHA both as the ethyl esters (380 mg EPA and 190 mg DHA)
Study NCT02101970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Capsule
Study NCT02101970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet and Exercise
Description: Increasing physical activity required over 6 month period to be tracked by a Fitbit. Diet based on caloric intake and eating approved foods.
Study NCT02101970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet and Exercise
Description: Increasing physical activity required over 6 month period to be tracked by a Fitbit. Diet based on caloric intake and eating approved foods.
Study NCT01166451 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-iron formula
Description: Infants randomly assigned at 6 months of age to receive low-iron formula (average 2.3 mg/L, range 1.6 - 2.4 mg/L) until 12 months of age. Low-iron formula distributed in powdered form. Project personnel visited infants' homes weekly to record measures of powdered formula used per day. Formula consumption was also verified by the number of cans given by the clinic nurse at each visit (regular pediatric visits and monthly clinic appointments until 12 months of age.)
Study NCT01166451 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-iron formula
Description: Infants randomly assigned at 6 months of age to receive high-iron formula (average 12.7 mg/L) until 12 months of age. High-iron formula distributed in powdered form. Project personnel visited infants' homes weekly to record measures of powdered formula used per day. Formula consumption was also verified by the number of cans given by the clinic nurse at each visit (regular pediatric visits and monthly clinic appointments until 12 months of age.)
Study NCT02548026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Eating Frequency (High EF)
Description: Free-living participants complete a 21-day high eating frequency (high EF) Phase in which they consume all daily energy at 8 eating occasions.
Study NCT02548026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Eating Frequency (Low EF)
Description: Free-living participants complete a 21-day low eating frequency (low EF) Phase in which they consume all daily energy at 3 eating occasions.
Study NCT01912209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Everyday Health
Description: MyEveryday Health is a web-based nutritional and lifestyle management program. The program includes personalized diet and weight guidance, meal planners, shopping list generator, recipe finder, weight tracker and dining out and fast food guides. Based on specific algorithms, tips and suggestions on how to make changes in their diet and lifestyle will be give each time the subject logs in. The MyEverydayHealth website will also be available as an app for their smart phone to the participants. If they choose to use the app, daily reminders to log in and use their tools will be sent, along with motivating tool/tips/tricks to stay with the program.
Study NCT02167945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: Tablet for oral use
Study NCT02167945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: Tablet for oral use
Study NCT02167945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin was provided as 200 mg tablets, and dosed based on weight, 1000 to 1200 mg divided twice daily per local label. For example, for participants weighing \< 75 kg, RBV may have been taken orally as 2 tablets in the morning and 3 tablets in the evening which corresponds to a 1000 mg total daily dose. For participants weighing ≥ 75 kg, RBV may have been taken orally as 3 tablets in the morning and 3 tablets in the evening which corresponds to a 1200 mg total daily dose.
Study NCT03545256 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: outpatient surgery for T1-N0 or T2-N0 cancers of the oral cavity or oropharynx with lymph node search
Description: The surgical procedure associated with the sentinel lymph node technique is carried out in two stages:~- Lymphoscintigraphy at Day-1 : This is the identification of the lymphatic network of the patient by a prior injection of radioactive tracer, nanocolloids labeled with technetium99, around the primary tumor. A planar CT image acquisition is performed to identify the sentinel lymph nodes (Gs(s)) which are then marked on the skin with an indelible marker.~Surgery on D0:~The patient is admitted to the hospital at 7:00 am in outpatient unit. He is reviewed by the anesthetist before the intervention and is transferred to the operating room for the intervention under AG.~The main tumor is operated by mouth.
Study NCT01363869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea extracts 2 gm/day
Description: Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 2 grams per day.
Study NCT01363869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea extracts 4 gm/day
Description: Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 4 grams per day.
Study NCT01363869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea extracts 6 gm/day
Description: Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 6 grams per day.
Study NCT02800655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Health Feedback System
Description: This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their ARV medications. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their ARV medications.~Other Names:~DHFS
Study NCT04429815 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serological test for COVID-19.
Description: Serological test for COVID-19 performed as part of standard of care.
Study NCT03797105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-Based Obesity Intervention (FLOW)
Description: The intervention consisted of nutrition lessons based on the traffic light diet, circuit-based physical activity, behavior modification techniques (token economy system, goal setting, self-monitoring), and parental involvement (materials sent home and monthly parent meetings). 80% of time was spent on physical activity and 20% was spent on nutrition. Behavior modification was incorporated into both physical activity and nutrition time. Specifically, instruction and activity time during PE class lasted approximately 40 minutes.
Study NCT04355598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine-Prilocaine cream
Description: 2 mL of the Lidocaine-Prilocaine cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
Study NCT04355598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glyceryl trinitrate cream
Description: 2 mL of the glyceryl trinitrate cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
Study NCT04355598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo cream
Description: 2 mL of the placebo cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
Study NCT03077932 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: App Development and Open Pilot
Description: Phase 1 (app development) will consist of: 1) development of the BetterOFF prototype; and 2) series of usability studies with patients interested in discontinuing opioid medication.~Phase 2 (open pilot) will involve conducting a 12-week open pilot trial (n=20) to test the feasibility and acceptability of the BetterOFF app with patients tapering from opiate medication.
Study NCT03548441 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Patients receiving surgical treatment undergo various types of posterior decompressive surgery with or without spinal fusion. The method used for decompressive surgery or fusions is determined solely by the surgeon.
Study NCT03548441 — intervention group
Intervention type: OTHER
Intervention: Non-surgical management
Description: Patients managing lumbar spinal stenosis non-surgically are either referred to rehabilitation primary health care center or referred back to their general practitioner for treatment. Treatment may include physiotherapy, chiropractic treatment, lifestyle changes and/or pain management. Post-surgically patients may also be referred to rehabilitation at a primary health care center.
Study NCT02328898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cre8 Stent
Description: Comparison of the Resolute Integrity stent with the Cre8 stent.
Study NCT02328898 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity stent
Study NCT02280213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: Direct laryngoscopy 1
Study NCT02280213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAC
Description: Direct laryngoscopy 2
Study NCT02280213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WIS
Description: Direct laryngoscopy 3
Study NCT02280213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHIL
Description: Direct laryngoscopy 4
Study NCT01442259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Study NCT05083455 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban
Description: Any rivaroxaban dispensing claim is used as the exposure group
Study NCT05083455 — intervention group
Intervention type: DRUG
Intervention: Enoxaparin
Description: Any enoxaparin dispensing claim is used as the reference group
Study NCT03247894 — intervention group
Intervention type: OTHER
Intervention: Data search
Description: Patients data were searched for the patients with MS, who laboured in tertiary perinatology center in the study period
Study NCT00732745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT03652688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nightlife Safety Plans (NSP)
Description: A group approach to reducing unwanted outcomes was implemented prior to entering the nightclub. The focus was on peer-to-peer intervention.
Study NCT03652688 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Fire Safety
Description: Groups were asked to read information about fire safety prior to entering the club and to answer some questions about fire safety
Study NCT03932201 — intervention group
Intervention type: DRUG
Intervention: Damoctocog alfa pegol (Jivi, Bay94-9027)
Description: Follow clinical practice. BAY94-9027 is a B-domain-deleted recombinant factor VIII (rFVIII) product site-specifically conjugated to a single (dual 30-kDa branched) 60-kDa polyethylene glycol (PEG) molecule. BAY 94-9027 is intended for prophylaxis and treatment of bleeds in patients with hemophilia A aged ≥12 years, with a narrow, predictable weekly dose that allows for the treatment regimen to be tailored to individual patient needs.
Study NCT00732745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Given IV
Study NCT00732745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00732745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Given IV
Study NCT00732745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Description: Given orally
Study NCT00732745 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT02769624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil
Description: A dose of 18mcg (3 breaths) will be administered 3 times: at baseline, 1.5 hrs. post baseline and then again 2 hrs later following maximal exercise testing.
Study NCT02769624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 breaths of placebo (via inhalation devices) will be administered 3 times: at baseline, 1.5 hrs. post baseline and then again 2 hrs later following maximal exercise testing.
Study NCT00097357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Tablets, Oral, 12 +/- 2 days
Study NCT00097357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Injection, SQ, Q12H, 12 +/- 2 days
Study NCT00097357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Tablets, Oral, QD, 12 +/- 2 days
Study NCT00097357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin Placebo
Description: Injection, SQ, BID, 12 +/- 2 days
Study NCT00097357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban Placebo
Description: Tablets, Oral, BID, 12 +/- 2 days
Study NCT02940067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MedEx
Description: A combination of dietary and exercise interventions over four weeks before scheduled pancreatic surgery
Study NCT04205890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: The ketamine will be injected per the doctor's orders to achieve a dissociative state; dosage varies between 75mg - 1000mg depending on every individual's unique treatment plan.
Study NCT02274610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel-PNP
Description: Docetaxel Polymeric Nanoparticle Formulation
Study NCT02274610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: Docetaxel
Study NCT02887131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic CT of the ankle
Description: during inversion and eversion mouvement, with Aquilion One Toshiba scanner
Study NCT02986594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study NCT02986594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Study NCT01640457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOVOCART® Disc plus
Description: Autologous Disc Chondrocyte Transplantation System (ADCT)
Study NCT01640457 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NOVOCART® Disc basic
Description: ADCT (Media with no active cell component)
Study NCT01450176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine hydrochloride 0.2%
Description: 1 drop in each eye once daily for 2 weeks
Study NCT01450176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bepotastine besilate ophthalmic solution 1.5%
Description: 1 drop in each eye twice daily for 2 weeks
Study NCT05213988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: Intermittent fasting meal pattern
Study NCT05213988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrates
Description: Bezafibrate 400 mg/day
Study NCT05213988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate/High-Protein diet
Description: Low-calorie, low-carbohydrate, high-protein diet
Study NCT04039997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPRMeter
Description: teaching resuscitation with application of cpr feedback device
Study NCT04039997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual chest compression
Description: Manual chest compression
Study NCT01004302 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ventral capsular/ventral striatal gamma capsulotomy
Description: Comparison of active radiosurgical with sham radiosurgeries
Study NCT01004302 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: ventral capsular/ventral striatal gamma capsulotomy
Description: Comparison of active radiosurgical with sham radiosurgeries
Study NCT02693314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jarro-Dophilus EPS® (5 billion CFU/capsule)
Description: One capsule containing 5 billion CFU of the probiotic mix (Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus casei, Pediococcus acidilactici, Bifidobacteria breve, Bifidobacteria longum, Lactobacillus plantarum and Lactobacillus lactis ssp. lactis) will be taken once a day for a period of 28 days.